Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 20];9(6):s606. Available from: https://skin.dermsquared.com/skin/article/view/3881